ClinicalTrials.gov record
Completed Phase 3 Interventional

Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001

ClinicalTrials.gov ID: NCT02336685

Public ClinicalTrials.gov record NCT02336685. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 3:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Adjunctive Therapy in Subjects With Signs and Symptoms of Osteoarthritis of the Hip or Knee

Study identification

NCT ID
NCT02336685
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Janssen Research & Development, LLC
Industry
Enrollment
79 participants

Conditions and interventions

Interventions

  • Fulranumab 1 mg Drug
  • Fulranumab 3 mg Drug
  • Opioid Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 99 Years
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 6, 2015
Primary completion
Sep 15, 2016
Completion
Sep 15, 2016
Last update posted
Oct 1, 2017

2015 – 2016

United States locations

U.S. sites
36
U.S. states
21
U.S. cities
36
Facility City State ZIP Site status
Not listed Birmingham Alabama
Not listed Huntsville Alabama
Not listed Cerritos California
Not listed Denver Colorado
Not listed Stamford Connecticut
Not listed Lewes Delaware
Not listed Newark Delaware
Not listed Crystal River Florida
Not listed Fort Lauderdale Florida
Not listed Hialeah Florida
Not listed Opa-locka Florida
Not listed Port Orange Florida
Not listed Marietta Georgia
Not listed Woodstock Georgia
Not listed Chicago Illinois
Not listed Rockford Illinois
Not listed Prairie Village Kansas
Not listed Lake Charles Louisiana
Not listed New Orleans Louisiana
Not listed Frederick Maryland
Not listed Worcester Massachusetts
Not listed Las Vegas Nevada
Not listed Albuquerque New Mexico
Not listed Brooklyn New York
Not listed Lake Success New York
Not listed Oklahoma City Oklahoma
Not listed Downingtown Pennsylvania
Not listed Duncansville Pennsylvania
Not listed Philadelphia Pennsylvania
Not listed Wyomissing Pennsylvania
Not listed Jackson Tennessee
Not listed Austin Texas
Not listed Dallas Texas
Not listed Houston Texas
Not listed West Jordan Utah
Not listed Richmond Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02336685, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 1, 2017 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02336685 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →